- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michel Michaelides Dives Into How Gene Therapy Can Treat Retinitis Pigmentosa
Gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and there is likely to be an increase in approved gene therapies for ophthalmic conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Michel Michaelides, MD, FACP, explains how gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and how it could be used in the future of eye care. Michaelides is a consultant ophthalmologist at Moorfields Eye Hospital in the Department of Medical Retina, Inherited Eye Disease and Paediatric Ophthalmology and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Transcript
What is the significance of the RPGR (GTPase regulator) gene as it pertains to retinitis pigmentosa and how can gene therapy address it?
Retinitis pigmentosa [RP] is genetically very variable with more than 100 different genes that cause RP. RPGR is one of the more common causes of RP. It tends to be one of the more severe forms as well. So it's particularly meaningful that we are on the cusp of potentially having an approvable drug for RPGR. So, fingers crossed for the phase 3 study that is being undertaken currently.
How do you expect for gene therapy for the treatment of retinal diseases and other ophthalmic conditions to develop in the future?
So, I'm very optimistic....there have been a couple of studies that haven't quite achieved their primary end point recently, but I think that's to be expected in drug development. We have an approved therapy for one of our rarer conditions. And I'm certain there will be an increase in approved drugs over the next 5 years to really make a positive impact on our patients lives.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
